Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02659098 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT02659098 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 21 participants.
The verdict
NCT02659098, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and performance profile of the suprachoroidal surgical approach and the Delivery System.
Interventions
- DRUG CNTO 2476 3.0 x 10^5 cells
- DEVICE Subretinal Delivery System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2015-12-04 |
| Est. Completion | 2019-06-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02659098
The ClinicalTrials.gov registry entry for NCT02659098 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CNTO 2476 3.0 x 10^5 cells is the first listed.
NCT02659098 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02659098 about?
NCT02659098 is a clinical study titled "A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy". The purpose of this study is to evaluate the safety and performance profile of the suprachoroidal surgical approach and the Delivery System.
What is the current status of trial NCT02659098?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2015-12-04. Estimated completion is 2019-06-05.
What interventions are being tested in trial NCT02659098?
The interventions under investigation include: CNTO 2476 3.0 x 10^5 cells (DRUG), Subretinal Delivery System (DEVICE).
Who is sponsoring clinical trial NCT02659098?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.